Intermittent Versus Daily Eltrombopag Dosage Protocols for the Treatment of Primary Immune Thrombocytopenia: Real-Life Experience

Overview

Journal J Blood Med

Publisher Dove Medical Press

Specialty Hematology

Date 2021 Jan 8

PMID 33414648

Authors

Tamer A Elbedewy

Mohamed A Elsebaey

Reem A Elkholy

Dina M Tahoon

Samah A Elshweikh

Affiliations

Soon will be listed here.

Abstract

Introduction/aim: Eltrombopag is recommended for the treatment of refractory immune thrombocytopenia (ITP). Based on its half-life, it may be practical to use an intermittent dosage. Our aim was to compare the effectiveness and safety of intermittent vs daily eltrombopag dosage protocols for the treatment of primary ITP refractory to prior therapies.

Patients And Methods: This was a retrospective study, and 34 adult primary ITP patients refractory to prior therapies were included in our analysis. Eltrombopag was used in this study. The patients were divided into daily eltrombopag dosage and intermittent eltrombopag dosage groups. Eltrombopag effectiveness was assessed regarding platelet count and bleeding resolution. Safety was assessed via adverse events reporting.

Results: In the daily eltrombopag dosage group, overall response (OR), complete response (CR), partial response (PR), and relapse rates were 69.23%, 53.85%, 15.38%, and 30.77%, respectively. In the intermittent eltrombopag dosage group, OR, CR, PR, and relapse rates were 68.75%, 50%, 18.75%, and 31.25%, respectively. Comparison between daily and intermittent eltrombopag dosage groups as regards CR, PR, relapse, relapse-free survival and adverse events showed insignificant differences.

Conclusion: Intermittent eltrombopag dosage is safe and effective in patients with ITP refractory to prior therapies and comparable to the daily eltrombopag dosage.

References

Cheng G, Saleh M, Marcher C, Vasey S, Mayer B, Aivado M . Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2010; 377(9763):393-402. DOI: 10.1016/S0140-6736(10)60959-2. View

Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel J . Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013; 121(14):2596-606. DOI: 10.1182/blood-2012-07-442392. View

Palandri F, Polverelli N, Sollazzo D, Romano M, Catani L, Cavo M . Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016; 91(4):E267-72. DOI: 10.1002/ajh.24310. View

Wire M, Bruce J, Gauvin J, Pendry C, McGuire S, Qian Y . A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when.... Clin Ther. 2012; 34(3):699-709. DOI: 10.1016/j.clinthera.2012.01.011. View

Audia S, Mahevas M, Samson M, Godeau B, Bonnotte B . Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017; 16(6):620-632. DOI: 10.1016/j.autrev.2017.04.012. View

Elgebaly A, El Ashal G, Elfil M, Menshawy A . Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials. Clin Appl Thromb Hemost. 2016; 23(8):928-937. DOI: 10.1177/1076029616663849. View

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

Fogarty P, Tarantino M, Brainsky A, Signorovitch J, Grotzinger K . Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2011; 28(1):79-87. DOI: 10.1185/03007995.2011.644849. View

Ghadaki B, Nazi I, Kelton J, Arnold D . Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013; 53(11):2807-12. PMC: 3938454. DOI: 10.1111/trf.12139. View

10.

Williams D, Peng B, Bailey C, Wire M, Deng Y, Park J . Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009; 31(4):764-76. DOI: 10.1016/j.clinthera.2009.04.010. View

11.

Al-Samkari H, Kuter D . An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018; 84(11):2673-2677. PMC: 6177710. DOI: 10.1111/bcp.13717. View

12.

Mithoowani S, Gregory-Miller K, Goy J, Miller M, Wang G, Noroozi N . High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016; 3(10):e489-e496. DOI: 10.1016/S2352-3026(16)30109-0. View

13.

Cuker A, Cines D, Neunert C . Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol. 2016; 23(5):479-85. DOI: 10.1097/MOH.0000000000000270. View

14.

Brynes R, Wong R, Thein M, Bakshi K, Burgess P, Theodore D . A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia. Acta Haematol. 2016; 137(2):66-72. DOI: 10.1159/000452992. View

15.

Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther M . The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190-207. DOI: 10.1182/blood-2010-08-302984. View

16.

Hayes S, Ouellet D, Zhang J, Wire M, Gibiansky E . Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2010; 51(10):1403-17. DOI: 10.1177/0091270010383019. View

17.

Jenkins J, Williams D, Deng Y, Uhl J, Kitchen V, Collins D . Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739-41. DOI: 10.1182/blood-2006-11-057968. View

18.

Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N . The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2015; 95(2):239-44. DOI: 10.1007/s00277-015-2556-z. View

19.

Matschke J, Muller-Beissenhirtz H, Novotny J, Vester I, Hertenstein B, Eisele L . A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-Naïve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study. Acta Haematol. 2016; 136(2):101-7. DOI: 10.1159/000445420. View

20.

Gonzalez-Lopez T, Pascual C, Alvarez-Roman M, Fernandez-Fuertes F, Sanchez-Gonzalez B, Caparros I . Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2014; 90(3):E40-3. DOI: 10.1002/ajh.23900. View